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Abstract
Background: Posttraumatic Stress Disorder (PTSD) may occur in patients after exposure to a life-threatening illness.
About one out of six patients develop clinically relevant levels of PTSD symptoms after acute myocardial infarction
(MI). Symptoms of PTSD are associated with impaired quality of life and increase the risk of recurrent cardiovascular
events. The main hypothesis of the MI-SPRINT study is that trauma-focused psychological counseling is more
effective than non-trauma focused counseling in preventing posttraumatic stress after acute MI.
Methods/Design: The study is a single-center, randomized controlled psychological trial with two active
intervention arms. The sample consists of 426 patients aged 18 years or older who are at ‘high risk’ to develop
clinically relevant posttraumatic stress symptoms. ‘High risk’ patients are identified with three single-item questions
with a numeric rating scale (0 to 10) asking about ‘pain during MI’, ‘fear of dying until admission’ and/or ‘worrying
and feeling helpless when being told about having MI’. Exclusion criteria are emergency heart surgery, severe
comorbidities, current severe depression, disorientation, cognitive impairment and suicidal ideation. Patients will be
randomly allocated to a single 45-minute counseling session targeting either specific MI-triggered traumatic
reactions (that is, the verum intervention) or the general role of psychosocial stress in coronary heart disease (that is,
the control intervention). The session will take place in the coronary care unit within 48 hours, by the bedside, after
patients have reached stable circulatory conditions. Each patient will additionally receive an illustrated information
booklet as study material. Sociodemographic factors, psychosocial and medical data, and cardiometabolic risk
factors will be assessed during hospitalization. The primary outcome is the interviewer-rated posttraumatic stress
level at three-month follow-up, which is hypothesized to be at least 20% lower in the verum group than in the
control group using the t-test. Secondary outcomes are posttraumatic stress levels at 12-month follow-up, and
psychosocial functioning and cardiometabolic risk factors at both follow-up assessments.
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Discussion: If the verum intervention proves to be effective, the study will be the first to show that a brief trauma-
focused psychological intervention delivered within a somatic health care setting can reduce the incidence of
posttraumatic stress in acute MI patients.
Trial registration: ClinicalTrials.gov: NCT01781247
Keywords: Anxiety disorder, Biomarkers, Cardiovascular disease, Counseling, Myocardial infarction, Posttraumatic
stress disorder, Prevention, Psychological stress, Psychotherapy, Randomized controlled trial
Background
Posttraumatic Stress Disorder (PTSD) is a mental dis-
order that may occur after the experience of a traumatic
event. According to the fourth edition of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV),
PTSD is characterized by three distinct clusters of symp-
toms consisting of 1) re-experiencing of the traumatic
event (for example, in thoughts or dreams), 2) avoidance
of reminders of the event and emotional numbing and 3)
hyperarousal (for example, irritability and sleep problems).
These symptoms must last for at least one month and
cause significant problems in important areas of daily life
[1]. Besides man-made and disaster-related traumatic
experiences (for example, combat exposure, motor vehicle
accidents, hurricanes), life-threatening illnesses, such as
myocardial infarction (MI), can also cause PTSD [2-6]. A
meta-analysis on clinically significant PTSD symptoms
after acute coronary syndromes (ACS) found a prevalence
of 16% (95% CI, 13 to 20%) [7]; two-thirds of patients con-
tinue to suffer from PTSD two years after MI [8].
Several sociodemographic and psychosocial risk fac-
tors for the risk of MI-triggered PTSD have been identi-
fied, including young age [9] and increased distress
perceived during MI [10]. While MI-related threat to
life, helplessness and pain are predictive of PTSD, ob-
jective markers of myocardial damage such as cardiac
enzyme levels and left ventricular ejection fraction are
not predictive [9,11,12]. Less than optimal care processes
like emergency department crowding might contribute to
MI patients’ sense of life threat and decreased control,
thereby increasing the risk of developing posttraumatic
stress [13].
PTSD is associated with impaired quality of life, social
functioning, and high economic burden to the society
[14-16]. PTSD and posttraumatic stress along a con-
tinuum of severity are predictive of incident cardiovascular
disease morbidity and mortality [17-20]. A meta-analysis
on three prospective studies with a total of 609 ACS
patients showed that PTSD symptoms also worsen cardio-
vascular prognosis with a two-fold (95% CI, 1.7 to 2.4)
excess risk [7]. Moreover, this relationship is maintained
in studies controlling for other prognostic risk factors,
including traditional cardiovascular disease (CVD) risk
factors, MI severity, and depressive symptoms [21-23].
PTSD might exert its ‘cardiotoxic’ effect by several
pathways and mechanisms. In patients with coronary
heart disease (CHD), PTSD is associated with poor
health behaviors, including low level of physical activity,
smoking, and nonadherence with cardiac medications [24].
Commonly observed dysregulation of the hypothalamic-
pituitary-adrenal axis and autonomic nervous dysfunction
in PTSD might directly underlie a variety of physiological
changes potentially increasing the atherothrombotic risk
[25]. Accordingly, several cardiometabolic risk factors and
markers are associated with PTSD: endothelial dysfunction
[26], dyslipidemia [27], elevated resting blood pressure and
heart rate [28], low-grade inflammation [29,30], and
increased coagulation activity [31].
Because of its association with poor mental and cardio-
vascular health, the prevention of PTSD development after
MI is of high clinical relevance. A systematic review and
meta-analysis of randomized controlled trials of early psy-
chological interventions to prevent symptoms of PTSD in
individuals exposed to a specific traumatic event found a
benefit for individuals with early symptoms of traumatic
stress as opposed to those with no such symptoms and if
the intervention was trauma-focused [32,33]. There was no
evidence for a harmful effect of such early interventions as
long as compulsory psychological debriefing of traumatized
patients was avoided [33,34]. To improve adaptation to car-
diac events, an approach that uses cognitive (re)structuring
and an individual patient’s resources (for example, social
support, distraction, structure, helping patients regaining
control, building confidence in their future abilities to
successfully cope with the MI, enhancing resilience) is
warranted [35-37]. It follows from the above literature
that to prevent PTSD symptoms after MI, a trauma-
focused intervention is needed, whereas an intervention
that excludes targeting MI as a trauma is not effective.
The primary aim of our randomized-controlled trial is
to examine whether the development of posttraumatic
stress can be reduced by a single counseling session of 45
minutes targeting MI-triggered traumatic reactions (that
is, the verum intervention). The effect of this counseling
session will be tested against a control intervention
targeting the general role of psychosocial stress in CHD.
The verum and control interventions are both adminis-
tered to patients at high risk to develop PTSD within a
Meister et al. Trials 2013, 14:329 Page 2 of 11
http://www.trialsjournal.com/content/14/1/329
setting of a coronary care unit (CCU) within 48 hours by
the bedside after patients having reached stable circulatory
conditions. Secondary aims of our trial are to investigate
psychosocial functioning and cardiometabolic risk markers
between the two active intervention arms.
Our main hypothesis is that trauma-focused psycho-
logical counseling is more effective than non-trauma
focused counseling for reducing posttraumatic stress after
acute MI. Specifically, we predict that compared with the
control group, the verum group will report at least 20%
lower posttraumatic stress levels at three months after MI
as rated by blinded interviewers (primary outcome). We
expect that this group difference will persist for up to 12
months. Compared to the control group, the verum group
will additionally show better psychosocial functioning and
a more favorable profile of cardiometabolic risk markers
after 3 and 12 months of follow-up (secondary outcomes).
Methods/Design
Design
The study uses a randomized controlled two-armed design
comparing a psychological counseling intervention (that
is, the verum intervention) with an active control inter-
vention after patient inclusion in the study. Sequence
generation is done in a 1:1 fashion based on a computer-
generated random list with randomly varying blocks of 20.
The randomization sequence is generated by the website
Research Randomizer (http://www.randomizer.org). The
list is concealed by instructed office personnel in the
study center of the Division of Psychosomatic Medicine,
University of Bern, Switzerland, who is unaware of any
patient information and localized off-site from the CCU.
Study therapists receive the information to provide either
the verum intervention or the control intervention directly
from the study center.
Sample size calculation
As opposed to the primary outcome, which is interviewer-
rated posttraumatic stress, the sample size calculation is
based on self-rated posttraumatic stress levels, which we
had previously collected from almost 300 post-MI patients
[12]. Based on these data we expect that patients at a high
risk to develop PTSD (compare to below for definition)
will show a mean score of 15.2 ± 10.1 (range 0 to 51)
on the self-rated Posttraumatic Diagnostic Scale (PDS)
at three months after MI. However, we cannot exclude
a non-specific beneficial effect of the control interven-
tion on PTSD symptom development. Therefore, we
assume that patients in the control group will decrease
their posttraumatic stress level by 1.0 PDS score point
to 14.2 score points. We defined a 20% decrease in the
posttraumatic stress level in the verum group compared
to the control group to be clinically meaningful. There-
fore, in order to achieve a 20% difference in posttraumatic
stress levels between the verum intervention and the
control group, the verum intervention should achieve a
reduction of 3.9 PDS score points from 15.2 to 11.3 to
show a clinically meaningful effect. Applying an alpha
error level of P = 0.05, a beta error level of 20% and a
group difference in the total PDS score of 2.9 ± 10.1, the
sample size to detect a significant difference of 20% in
posttraumatic stress levels between groups is n = 194
per group. Because of possible drop outs (including post-
MI mortality), we will oversample each group by 10%
(that is, n = 213 per group), yielding a total sample of
n = 426 eligible post-MI patients to be randomly allocated
to the two active intervention arms.
Study sample
Based on the recruitment experience from previous stud-
ies on PTSD in post-MI patients and other trials of the
study CCU, we predict to consecutively enroll the required
number of 426 eligible patients for the study within 24
months (between 1 January 2013 and 31 December 2014).
Figure 1 details the recruitment and participant flow. In
brief, patients with ST-segment elevation MI (STEMI) and
non-STEMI and referred to the CCU, Department of Car-
diology, Inselspital, Bern University Hospital, Switzerland,
are invited to participate in the study. The department’s
cardiologists make a diagnosis of STEMI or non-STEMI
per standard criteria as previously described [38]. The
average biennial admission rate of patients with STEMI
and non-STEMI to the CCU is approximately 3,000.
Following a secondary analysis of a previous data set
[12], about 900 (approximately 30%) of these will be
‘high risk patients’ in terms of perceiving a substantial
amount of distress during MI (compare to. paragraph
below for precise definition). Of these, we predict that
one third will not be accessible, mainly because they are
transferred to other hospitals early after coronary inter-
ventions or will not provide consent, leaving 600 patients
meeting inclusion criteria. One fourth of these will not be
eligible because they meet exclusion criteria or drop out
early.
MI-triggered distress to define ‘high risk’ patients is
assessed within 6 to 36 hours of hospital referral with
three single-item questions asking about the intensity of
pain, fear of dying and helplessness to be rated on a nu-
meric scale ranging from 0 to 10. Very similar single-
item questions referring to perceived distress during
ACS have been used in previous studies showing good
reliability and predictive value for psychosocial adapta-
tion and cardiovascular prognosis [39,40]. Those scoring
at least five points for ‘pain during MI’ plus at least five
points for ‘fear of dying until admission to the CCU’
and/or ‘worrying and feeling helpless when being told
about having MI’ are ‘high risk patients’.
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Timing of assessments
Patients will be assessed at three time points: on the CCU
within 48 hours after MI (T0), at three months after
discharge from the CCU (to assess acute posttraumatic
stress) (T1), and at 12 months after discharge from the
CCU (to assess chronic and late-onset posttraumatic
stress) (T2). It is critical to approach patients at the earli-
est possible time after referral because they will usually
stay for only 48 hours in the CCU before discharge.
Therefore, within 12 to 24 hours of admission to the CCU
(T0), all patients with STEMI/non-STEMI, aged 18 and
older, and with stable circulatory condition will be in-
formed about the planned study and are given a few hours
to consider their participation. The study therapist will ap-
proach all eligible patients to ask about their willingness
to participate in a single counseling session about the role
of psychological stress in CHD and the possibilities to
self-manage stress. Patients will be told that the pro-
vided information might be useful for good mental
functioning while building up their life after MI. The
patient will be told that if he/she agrees to participate
he/she will be randomized to either counseling session
A, targeting the more sudden and unexpected psycho-
logical stress which may occur in the aftermath of MI
(that is, the verum intervention) or to counseling ses-
sion B, targeting more general aspects about the role of
psychosocial stress in MI (that is, the control interven-
tion). During this information, study therapists avoid
any terminology specifically pertaining to trauma. After
having provided informed consent, and if reporting a
sufficient amount of distress from MI, they will undergo
medical and psychometric data assessment as specified
below.
Inclusion and exclusion criteria
Patients are included in the study if they are aged 18 or
older, have STEMI or non-STEMI, are in a stable circu-
latory condition according to the treating cardiologist,
and had perceived substantial distress during MI based
on the three screening questions targeting pain, fear of
dying, and helplessness. Patients are excluded from the
study if they have undergone emergency coronary artery
bypass graft surgery, suffer from a serious comorbid dis-
ease likely to cause death within one year, currently have
current severe depression (per the cardiologist’s history
and clinical impression), are not fully oriented and/or cog-
nitively impaired, have insufficient knowledge of German,
Figure 1 Recruitment and participant flow. MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation
myocardial infarction; PTSD, posttraumatic stress disorder.
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affirm suicidal ideation in the last two weeks, or are
participating in another randomized controlled trial in
the Cardiology Department.
Intervention
Study therapists with a master’s degree in clinical psych-
ology deliver the intervention within 48 hours of admis-
sion, as a single session of 45 minutes with the therapist
by the bedside. Therapists are trained and supervised by
senior clinical psychotherapists with degrees in psych-
ology or psychiatry from the Clinical Psychology and
Psychotherapy, Department of Psychology, University of
Bern and Department of Psychiatry and Psychotherapy,
University Hospital Zurich, Switzerland. Study therapists
undergo at least 30 hours of training prior to beginning
the trial. Two independent experts will rate 30 audiotaped
intervention sequences to monitor adherence of study
therapists to the intervention protocol. In addition, 50
patients from each intervention group will be asked to
indicate their perception as to whether they belong to
the intervention group A (that is, the verum group) or B
(that is, the control group).
Table 1 details the components and topics of the two
interventions. Each intervention consists of a counsel-
ing session of 45 minutes plus delivery of a colored
information booklet for patients to deepen the oral
information. Text and figures of the two booklets are
specific to each mode of intervention and also serve as
the basis for interacting with the patient. For the first
half of the session, therapists will primarily cover
topics that are of most immediate concern to the indi-
vidual patient. For instance, when asking about previ-
ous stressful situations (in the control intervention)
and the patient mentions a difficult situation at work,
the discussion will be on job stress. Other forms of
stressful life circumstances will not be covered but are
dealt with in the information booklet. Nevertheless,
during the course of counseling, therapists are re-
quired to inform about key topics, for instance, in the
verum intervention, that it is a normal and common
experience to perceive MI as stressful.
The 45-minute verum intervention uses an educational
and resource-oriented approach targeting individual pa-
tient resources and cognitive (re)structuring to specific-
ally prevent MI-triggered traumatic reactions. The study
therapist will introduce the concept of psychological
trauma and PTSD and how MI patients may deal and
cope with posttraumatic stress symptoms should these
occur after MI [36,37,41,42]. The focus of the 45-minute
control intervention is to inform patients about the role
of psychosocial stress in CHD in general and how this
information might be considered in re-building a life
after MI for the sake of proper mental functioning
[43-47]. Most importantly, the control intervention will
completely avoid any terminology specifically pertaining
to ‘trauma’, including the MI as a trauma.
Measures
Table 2 shows all health outcomes in the MI-SPRINT
study with the timing of their assessment. All psychomet-
ric questionnaires used in the MI-SPRINT study are vali-
dated in the German language [48-77]. We will apply the
Clinician-Administered PTSD Scale (CAPS) to assess our
primary outcome (that is, interviewer-rated posttraumatic
stress level at three months after the intervention) [48].
Assessors will be blinded to the type of intervention and
asked to indicate their guess as to whether the patient had
received the verum intervention or the control interven-
tion. The German version of the CAPS shows good in-
ternal consistency for the severity score of all 17 PTSD
symptom items (Cronbach’s α = 0.88 to 0.92) as defined
by the DSMcpIV [49]. The frequency and intensity of each
Table 1 Topics and questions covered by the two interventions
Verum group Control group
a) What is a trauma? Why can acute MI be understood as a traumatic experience? a) What is psychosocial stress and when can it become
dangerous?
b) Why can MI have a psychological impact? b) Why do not all people react the same way to psychosocial
stress?
c) How do patients cope with and adjust to their MI experience? c) Which types of psychosocial stress are known to potentially
have an influence on CHD and cardiac prognosis?
d) What are the most common reactions to traumatically experienced MI? d) How can psychosocial stress affect a healthy life style,
adherence to cardiac therapy, and cardiovascular biology?
e) Other reactions to traumatically experienced MI. e) What can be done to reduce psychosocial stress?
f) What is PTSD, in general and related to MI?
g) Why do not all patients react in the same way to MI?
h) Coping with the trauma, tackling avoidance, coping with safety behaviors,
anxiety, anger/irritability, sleeping problems, alcohol and medication
i) How to get professional help
CHD, coronary heart disease; MI, myocardial infarction; PTSD, posttraumatic stress disorder.
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Table 2 Measures at hospital referral (T0), three-month (T1) and twelve-month (T2) follow-up
Variables T0 T1 T2
Sociodemographic and medical variables
Demographics: for example, gender age, marital status x
Medical history: for example, family history of coronary artery disease, diabetes mellitus, hypertension x
Lifestyle and health behavior: smoking history, alcohol consumption, physical exercise, sleep quality x x x
Prescribed medication before CCU referral x
Medication administered during CCU stay x
Medication at discharge from CCU x
Context of hospital referral: for example, patient agitation state at arrival on CCU, hectic conditions on CCU at patient arrival x
Clinical presentation at time of arrival at CCU: for example, total number of stents implanted, number of diseased coronary vessels, left
ventricular function, Killip classification, pain onset
x
Psychometric data
Clinician-administered PTSD Scale (CAPS) [48,49] x x
Posttraumatic Diagnostic Scale (PDS) [50,51] x x x
PTSD screening with three items from the structured clinical interview for DSM-PTSD [52,53] x
Acute Stress Disorder Scale (ASDS) [54,55] x
Illness Perception Questionnaire-Revised (IPQ-R) [56,57] x
Beck Depression Inventory (BDI) [58-60] x x
Type D Scale (DS14) [61,62] x
Toronto Alexithymia Scale (TAS-20) [63,64] x
Resilience Scale [65,66] x x
EuroQol group five dimension questionnaire (EQ-5D) [67,68] x x x
Symptom Checklist-9 (SCL-9-K) [69,70] x x x
Enhancing Recovery in Coronary Heart Disease Social Support Inventory (ESSI) [71,72] x x
Global Mood Scale (GMS) [73] x x
Coping Inventory for Stressful Situations (CISS) [74,75] x
Heart drawing [76,77] x
Laboratory Analysis
Metabolic factors: total cholesterol, LDL-C, HDL-C, triglycerides, glucose, HbA1cRoutine laboratory measures: alanine transaminase,
creatinine, hemoglobin, hematocrit, leukocytes, thrombocytes
x x x
Inflammation markers: hs-CRP, IL-6, TNF-α, IL-4 x x x
Hemostasis markers: fibrinogen, D-dimer, VWF antigen x x x
Stress hormones: plasma cortisol, norepinephrine, epinephrine x x x
Heart rate variability: total power, high frequency power, low frequency power, low-to-high frequency power ratio x x x
Resting hemodynamics: heart rate, systolic/diastolic blood pressure x x x
Anthropometric measurements: body weight, height, body mass index; waist and hip circumferences, waist-to-hip ratio x x x
Developments since discharge from CCU/three-month assessment
Vitality status x x
Hospital referrals since discharge (including recurrent cardiovascular events) x x
General practioner visits x x
Specialist visits x x
Cardiac rehabilitation x x
Psychotherapy since discharge x x
Recurrent cardiac symptoms x x
Medication adherence x x
Functional status x x
Meister et al. Trials 2013, 14:329 Page 6 of 11
http://www.trialsjournal.com/content/14/1/329
symptom are rated between 0 (never) and 4 (almost
always). A symptom is given when frequency is at least
one point and intensity is at least two points. One of five
symptoms is required for criterion B (reexperiencing clus-
ter), three of seven symptoms for criterion C (avoidance
cluster), and two of five symptoms for criterion D
(hyperarousal cluster). The severity of PTSD is obtained
by adding up symptom scores of criteria B+C+D. Patients
will be diagnosed with syndromal PTSD if meeting criteria
B+C+D [1].
Cardiometabolic assessments
Fasting blood samples will be obtained at 6 am, within
24 hours after hospital referral, and directly sent to
accredited laboratories at the Bern University Hospital
to be processed within clinical routine on the same day.
For catecholamine and cytokine analyses, ethylene-
diamine-tetraacetic acid (EDTA) samples are centrifuged
once at 2,000 g for ten minutes at room temperature;
obtained plasma is frozen in CryoPure Tubes (Sarstedt,
Numbrecht, Germany) at −80°C until analysis.
A Modular P800 system with ion selective electrodes
and Cobas standard test kits (all Roche Diagnostics,
Rotkreuz, Switzerland) will be used to determine levels of
blood lipids, glucose, alanine transaminase, and creatinine
from heparin plasma samples. Hemoglobin A1c will be
determined in whole blood using high-performance liquid
chromatography on a HLC-723 G7 analyzer (Tosoh Corp.,
Tokyo, Japan). Hemoglobin, hematocrit, leukocyte and
thrombocyte counts will be determined from EDTA
plasma samples using the LH 750 analyzer (Beckman
Coulter, Miami, FL, USA).
Heparin plasma samples will be analyzed for high-
sensitivity C-reactive protein by a latex particle immuno-
turbidimetric assay on the Roche Modular P800 analyzer
(Roche Diagnostics, Rotkreuz, Switzerland). Levels of
tumor necrosis factor-α, interleukin-6, and interleukin-4
will be measured in EDTA plasma samples using luminex
technology (Bio-Plex Pro™ Cytokine Assays, Bio-Rad
Laboratories AG, Cressier, Switzerland).
Hemostasis markers will be determined from citrate
plasma samples. Fibrinogen clotting activity will be mea-
sured by the Clauss method on a Behring Coagulation sys-
tem automated analyzer using commercial reagents and
standard human plasma (Dade Behring AG, Düdingen,
Switzerland). D-dimer levels will be determined through
an enzyme-linked immunosorbent assay (Vidas-D-Dimer,
bioMérieux, Geneva, Switzerland). A quantitative, au-
tomated immunoassay will be used to determine von
Willebrand factor antigen (Siemens, Marburg, Germany).
Serum cortisol will be measured by competitive im-
munoassay using Roche Modular E170 (Roche Diagnostics,
Rotkreuz, Switzerland). Norepinephrine and epinephrine
concentration will be determined from EDTA plasma
samples by means of HPLC and electrochemical detection
after liquid-liquid extraction [78].
Heart rate and frequency domain measures of heart rate
variability will be assessed from five-minute electrocardio-
gram recordings with the Finometer using customized
software (TPD Biomedical Instruments, Amsterdam, The
Netherlands) and averaged across the recording period.
Blood pressure will be measured twice with an interval of
ten minutes with the automatic Omron M6W Blood Pres-
sure Monitor (Omron Healthcare Europe BV. Hoofddorp,
The Netherlands); the average systolic and diastolic blood
pressure will be computed for analysis.
The hip circumference measurement will be taken
around the widest portion of the buttocks. The waist cir-
cumference will be measured at the approximate mid-
point between the lower margin of the last palpable rib
and the top of the iliac crest. The measurement of body
weight will be performed with participants wearing no
shoes and light clothing to the nearest 0.1 kg with a
digital balance (Modell W41, Firma Migros, Switzerland)
at follow-up assessments, and to the nearest 0.5 kg by
history at hospital referral, because of potential fluid over-
load. Height will be measured with a reference tape to the
nearest 0.1 cm. Body mass index will be calculated by div-
iding the weight in kilograms by height in meters squared.
Ethical considerations
The study complies with the declaration of Helsinki.
The ethics committee of the State of Bern, Switzerland,
approved the study protocol. All potentially eligible
patients (that is, those meeting the inclusion criteria)
receive written information about the aim of the study,
benefits and risks of participation and the exact study
procedure before giving their written informed consent
to participate in the study that includes two follow-up
assessments. All participants are informed that they can
Table 2 Measures at hospital referral (T0), three-month (T1) and twelve-month (T2) follow-up (Continued)
Treatment adherence with information booklet x x
Major life events x x
Onset of new diagnosis x x
Current medication x x
CCU, coronary care unit; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein-cholesterol; hs-CRP, high-sensitive C-reactive protein; IL-6, interleukin-6; IL-4,
interleukin-4; LDL-C, low-density lipoprotein-cholesterol; TNF, tumor necrosis factor; VWF, von Willebrand factor.
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withdraw themselves from the study anytime. All pa-
tients are encouraged to first contact their primary care
physician in case they feel a need for mental health
treatment at any time during follow-up. However, these
patients will remain in the study, as it would be highly
unethical to ask them to refrain from seeking profes-
sional help during follow-up. Patients who are diagnosed
with syndromal PTSD at follow-up investigations are
told their diagnosis. Moreover, patients and their pri-
mary care physicians are informed about the possibility
of a referral to the Department of Clinical Psychology
and Psychotherapy, University of Bern, Switzerland to
receive treatment for PTSD.
To identify adverse reactions to the verum interven-
tion, two interim safety analyses will be performed after
subgroups of 130 and 260 patients on the primary effi-
cacy endpoint, that is, interviewer-rated posttraumatic
stress level at three months after the intervention. The
spending function approximating O’Brien-Fleming bound-
aries [79] will be used to determine criteria for the interim
and final analyses to protect the overall false positive
rate of the trial at P = 0.05. The study will be stopped
for inequality in outcome between the verum and con-
trol group if results reach a predefined level of statis-
tical significance at the two-sided alpha level of 0.001
and 0.014, respectively. The nominal two-sided signifi-
cance level for the final evaluation will be 0.045. This
provides us with a 3.3% and 44.2% chance of stopping
the trial after the first or second interim analysis,
respectively.
Statistical analyses
Data will be analyzed using the latest version of the Statis-
tical Package for the Social Sciences (SPSS Inc. Chicago, IL,
USA) with a significance level of P < 0.05 (two-tailed). Be-
fore analysis, all outcome variables will be tested for nor-
mality by the Kolmogorov-Smirnov test and, if necessary,
transformed to obtain a normal distribution. Differences in
variables between the two intervention groups will be cal-
culated using the t-test for continuous data and the chi-
squared test for categorical data. The primary outcome is
the severity of posttraumatic stress levels rated by the
CAPS interview at the three-month follow-up. Secondary
outcomes are measures of psychosocial functioning and
cardiometabolic biomarkers at three months follow-up
(primary analysis). Key secondary outcomes are quality of
life, plasma levels of C-reactive protein, D-dimer, cortisol
and norepinephrine, as well as high-frequency heart rate
variability. These outcomes are important indicators of
mental health functioning, low-grade inflammation and
coagulation activity as well as hypothalamic-pituitary ad-
renal axis and autonomic nervous system function. Re-
peated measures analysis of variance will be applied to test
for a change in posttraumatic stress levels and in measures
of psychosocial functioning and cardiometabolic bio-
markers between the two follow-up visits (secondary ana-
lysis). The relative risk for developing a diagnosis of PTSD
during follow-up in the control group compared to the
verum group will be calculated by means of logistic regres-
sion analysis. For a complementary sensitivity analysis, we
will apply univariate, multivariate and repeated measures
analysis of covariance taking into account sociodemo-
graphic, medical and psychosocial covariates, and received
psychotherapy during follow-up.
Missing values for questionnaire items will be replaced
using the expectation maximization algorithm [80]. If pa-
tients drop out during follow-up, we will carry forward the
last observed data points to impute missing endpoints.
Randomized patients who will not undergo the interven-
tion are excluded from the analysis. However, we will per-
form an additional analysis based on the intention-to-treat
principle with all randomized patients.
Discussion
The MI-SPRINT study is a randomized-controlled trial to
investigate whether a minimal psychological intervention
applied shortly after hospital referral may reduce the prob-
ability of developing clinician-rated posttraumatic stress
levels attributable to MI. If effective, the planned trial will
be the first to show that the development of posttraumatic
stress can successfully be reduced in MI patients at high
risk to develop PTSD through a single 45-minute counsel-
ing session that is feasibly (for example, not excessively
time-consuming) administered in a busy CCU setting.
Cardiac patients with high risk to develop PTSD have
generally limited access to early psychological care. There-
fore it is important to know whether such an intervention
bears the potential to become an integrative part of the
post-acute treatment phase of patients with acute MI to
improve quality of life and perhaps cardiovascular progno-
sis as well. Regarding the latter, a relative improvement of
the atherothrombotic risk profile in the verum group
might stimulate a larger intervention trial to possibly im-
prove cardiac prognosis in patients with high distress after
MI, as biologically plausible atherothrombotic mecha-
nisms would seem to be responsive to an early psycho-
logical intervention.
There are limitations to the study design. Firstly, only
those patients who are willing to participate in the study
and to fill in questionnaires will be screened; therefore, it
is possible that some severely distressed patients escape
the screening, as they may feel too overwhelmed by the
actual events for participating. Secondly, for feasibility rea-
sons, we did not include non-German speaking patients,
who constitute a significant part of the Swiss population.
Therefore, the generalizability of our study findings to
non-German speaking residents might be questioned.
Nonetheless, the prevalence rates of PTSD in ACS
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patients do not vary greatly by study location (United
States versus elsewhere, including Europe) [7]. Thirdly, al-
though the control intervention avoids trauma termin-
ology, an indirectly beneficial effect cannot fully be
excluded, for instance if patients in the control group
learn to better cope with general psychological distress.
In this case, however, a group difference in posttraumatic
stress levels that remains significant would only substanti-
ate an assumed benefit of the trauma-focused verum
intervention.
Several considerations on the design of the MI-SPRINT
trial will need to be taken into account for the interpret-
ation of study findings. We will assess posttraumatic stress
at three-month follow-up, although ACS-induced PTSD
symptoms at one-month might show greater variability
and have been associated with recurrent CVD events [22].
Although we plan an exploratory analysis to investigate
whether the intervention might offset recurrent CVD
events, larger trials with adequate power would be needed
for a reliable evaluation of this outcome. For both ethical
and methodological reasons, we excluded patients with
probably severe clinical depression who should receive
standard antidepressant treatment, an imperative which
would greatly complicate the protocol. A formal assess-
ment of severe depression with a psychiatric interview is
not feasible in this acute setting. A usual care control
group might yield greater effects for the verum interven-
tion, but such a design could not refute an interpretation
that the mere contact with the study therapist was effect-
ive. We assess the subjective perception of the environ-
ment of acute medical care but for logistic reasons are
unable to collect objective data on crowding or acuity of
adjacent patients during participants’ CCU stay.
The MI-SPRINT study has several strengths; foremost
its external validity, since MI patients are consecutively
recruited from the cardiology department of a tertiary
center with a wide rural and urban catchment area. In
addition, the assessed psychometric and biomedical out-
come variables and covariates are both well-established
and cutting-edge measures in behavioral cardiology stud-
ies. To this extent, they may provide us with important
novel insight into the prevention of posttraumatic stress
development after MI and its link with psychosocial func-
tioning and cardiometabolic risk, while also allowing us to
identify potential moderating and/or confounding factors
of these relationships. Finally, the MI-SPRINT study might
extend our knowledge about the benefits and limits of
psychological treatments for MI patients with a potential
to reduce the burden on the health care system.
Trial status
Recruitment of participants is ongoing; it began in January
2013 and is expected to end in December 2014. The final
follow-up investigation is scheduled for December 2015.
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